Pfizer Share Price

NSE: PFIZER

S Cap

₹ 4,990.40

-₹27.20 (-0.54%)

Last updated 13 Aug, 2026, 15:52 IST

Pfizer Share Price Today

As of 14 Aug 2026, Pfizer share price is ₹4,990.40. The stock opened at ₹5,045.80, compared to its previous close of ₹5,017.60. During today's trading session, Pfizer share price moved in the range of ₹4,941.30 to ₹5,050.40, with an average price of ₹4,995.85 for the day. Looking at its last 52-week, the stock has touched a low of ₹4,360.10 and a high of ₹5,873.50. On the performance front, Pfizer share price has declined by 0.93% over the last six months and is down 2.28% on a year-on-year basis.

₹4,941.30

0.54% down today

₹5,050.40

1D LOW

1D HIGH

Stock Performance

OutperformingBeat Nifty by 5.01 % in last 1 month

Shareholding Pattern

DIIDII decreased stake by 4.65%

Shareholding Pattern

FIIFII decreased stake by 41.33%

Pfizer Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹4,68,318-₹31,682 (-6.34%)

3 Year

₹6,53,442+₹1,53,442 (+30.69%)

5 Year

₹4,35,839-₹64,161 (-12.83%)

₹4,014.10₹6,021.10

Circuit Low

Circuit High

₹4,360.10₹5,873.50

52-Week Low

52-Week High

Circuit

₹4,014.10

₹6,021.10

52-week

₹4,360.10

₹5,873.50

About Pfizer

ISIN

INE182A01018

Sector Market Cap

₹ 1,394.87 Cr

Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.

Pfizer Financial Highlights

Revenue: Pfizer reported revenue of ₹867.69 crore in FY09 vs ₹982.61 crore in FY08. It showed a decrease of 11.70% on a yearly basis.
Operating Profit: Pfizer reported an operating profit of ₹210.01 crore in FY09 vs ₹419.13 crore in FY08. It showed a decrease of 49.89% on a year-on-year basis.
Net Profit: Pfizer reported a net profit of ₹137.12 crore in FY09 vs ₹299.58 crore in FY08. It showed a decrease of 54.23% on a yearly basis.

Pfizer Quarterly Result Highlights

Pfizer reported revenue of ₹698.01 crore in Jun 2026, compared with ₹669.95 crore in Mar 2026, representing an increase of 4.19% on a quarter-on-quarter (QoQ) basis.
Pfizer reported an operating profit of ₹276.68 crore in Jun 2026, compared with ₹268.82 crore in Mar 2026, representing an increase of 2.92% on a quarter-on-quarter (QoQ) basis.
Pfizer reported a profit of ₹204.47 crore in Jun 2026, compared with ₹199.82 crore in Mar 2026, reflecting an increase of 2.33% on a QoQ basis.
The earnings per share (EPS) of Pfizer stood at ₹157.92 during Jun 2026.

Know more

Promoters

63.92%

FII

1.65%

Other DII

5.12%

Retail and other

16.63%

Mutual funds

12.68%

Foreign institutions - FII

FII shareholding by period
Sep 2025	2.60%
Dec 2025	2.71%
Mar 2026	2.81%
Jun 2026	1.65%

Day

Open / Close

Change %

13 Aug 26

₹5,045.80 / ₹4,990.40

-0.54%

12 Aug 26

₹4,892.00 / ₹5,017.60

+2.43%

11 Aug 26

₹4,877.50 / ₹4,898.50

+0.43%

10 Aug 26

₹4,910.00 / ₹4,877.60

-0.06%

Mkt Cap Cr

1,394.87

P/E

31.24

P/B

5.46

ROE

19.78%

D/E

0.02

ROCE

27.27%

Div. Yield

1.50%

EPS(TTM)

157.92

Turnover

0.52

EV/EBITDA

18.31

Net Margin

28.67%

Op. Margin

41.39%

ROA

33.25%

Quick Ratio

5.31

Curr. Ratio

6.41

Mkt Cap Cr

1,394.87

P/E

31.24

P/B

5.46

ROE

19.78%

D/E

0.02

ROCE

27.27%

Div. Yield

1.50%

EPS(TTM)

157.92

Turnover

0.52

EV/EBITDA

18.31

Net Margin

28.67%

Op. Margin

41.39%

ROA

33.25%

Quick Ratio

5.31

Curr. Ratio

6.41

Based on fundamentals, this stock's

Performance

Excellent

Pfizer outperforming all market indices

Valuation

Fairly Valued

Pfizer appears to be fairly valued compared to its peers

Earnings

Very Poor

Pfizer revenue, operating profits and net profits have been degrowing

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,64,271.00	38.32	5.56	13.74%	0.61	17.33%	93.24	0.83%	0.48	10.90
Divis Laboratories	2,26,843.00	77.55	13.53	15.32%	0.00	19.56%	629.49	0.35%	0.55	98.19
Torrent Pharmaceuticals	1,86,000.00	86.27	22.12	25.49%	1.69	13.85%	222.76	0.69%	0.49	58.70
Zydus Lifesciences	1,20,099.00	26.15	4.43	18.59%	0.31	17.35%	237.30	0.08%	0.33	35.38
Cipla	1,18,027.00	35.18	3.43	11.27%	0.00	14.95%	423.36	0.89%	0.45	43.52
Lupin	1,03,549.00	18.65	4.61	23.76%	0.04	24.88%	659.05	0.79%	0.57	129.18
Mankind Pharma	1,00,137.00	48.43	6.14	11.74%	0.34	13.13%	397.02	0.04%	0.44	49.37
Dr. Reddy's Laboratories	1,00,073.00	31.44	2.63	11.07%	0.18	12.54%	377.96	0.67%	0.41	38.68
Laurus Labs	99,474.20	91.23	18.77	16.77%	0.40	16.14%	97.20	0.11%	0.67	13.72
Aurobindo Pharma	96,700.60	26.06	2.55	9.25%	0.19	11.76%	391.14	0.24%	0.38	41.58

Pfizer Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Nov 2006	Nov 2007	Nov 2008	Nov 2009
Revenue	769.8	1,019.76	982.61	867.69
Operating profit	162.64	451.34	419.13	210.01
Net profit	106.33	340	299.58	137.12

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹2,519.65	₹2,281.35	₹2,193.17	₹2,424.76
Other Income	₹187.95	₹172.25	₹180.51	₹101.05
Total Revenue	₹2,707.60	₹2,453.60	₹2,373.68	₹2,525.81
Total Expenses	₹1,682.77	₹1,610.32	₹1,635.56	₹1,734.80
Profit Before Tax	₹975.67	₹1,016.09	₹746.07	₹824.01
Tax	₹253.24	₹248.49	₹194.74	₹200.08
Profit After Tax	₹722.43	₹767.60	₹551.33	₹623.93
EPS - Basic	₹157.92	₹167.79	₹119.22	₹136.38
EPS - Diluted	₹157.92	₹167.79	₹120.51	₹136.38

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹975.67	₹1,016.09	₹746.07	₹824.01
Income before WC changes	₹912.85	₹770.52	₹656.75	₹692.75
Change in Assets	-₹12.27	₹7.23	-₹89.91	₹85.03
Change in Liabilities	₹52.46	₹38.22	-₹156.18	-₹119.52
Change in WC	₹40.19	₹45.45	-₹246.09	-₹34.49
Cash flow from Operations	₹967.57	₹659.75	₹256.84	₹355.68
Cash flow from Investing	-₹561.67	-₹71.34	₹53.70	-₹36.05
Cash flow from Financing	-₹798.31	-₹205.34	-₹235.14	-₹345.79
Total Cash Flow	-₹392.41	₹383.07	₹75.40	-₹26.16
Cash (Start of the year)	₹495.07	₹112.00	₹36.60	₹62.76
Cash (End of the year)	₹102.66	₹495.07	₹112.00	₹36.60

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹1,118.66	₹1,398.26	₹1,490.97	₹1,475.64
Current Assets	₹3,803.22	₹3,512.85	₹2,737.81	₹2,525.09
Total Assets	₹4,921.88	₹4,911.11	₹4,228.78	₹4,000.73
Current Liabilities	₹627.48	₹569.51	₹546.56	₹657.35
Net Current Asset	₹3,175.74	₹2,943.34	₹2,191.25	₹1,867.74
Non-Current Liabilities	₹91.50	₹124.19	₹86.68	₹136.08
Equity Capital	₹4,202.90	₹4,217.41	₹3,595.54	₹3,207.30
Total Equity & Liabilities	₹4,921.88	₹4,911.11	₹4,228.78	₹4,000.73